두시를 이용한 하태독법의 NC/Nga 생쥐에서 DNFB로 유발된 피부손상 완화 효과
Effects of Hataedock with Douchi on 2,4-dinitrofluorobenzene-induced Atopic Dermatitis-like Skin Lesion in NC/Nga Mice
0
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Hataedock is a Korean medical treatment that administers herbal extracts orally to newborn infants. This method is used for alleviating harmful heat and excreting fetal wastes by meconium. The purpose of this study was to evaluate anti-inflammatory effect of Hataedock method with Douchi on 2,4-dinitrofluorobenzene (DNFB)-induced atopic dermatitis (AD). The 3-week-old NC/Nga mice were divided into 3 groups: the control group (Ctrl), the AD-induced group (AE), and the Hataedock-treated group (GT). Only the GT group was treated with Hataedock at the 3rd week. After 28 days from Hataedock treatment, we induced AD-like dermatitis to the AE and GT group by DNFB. The effects of Hataedock were evaluated by immunohistochemical method. In the epithelium, PKC-positive reaction of the GT group was decreased by 57%. In the dermal papillae, IL-4-positive reaction was decreased by 34%. In the dermis, the distribution of degranulated mast cells was decreased and substance P-positive reaction was decreased by 49%. In the skin tissue, edema was decreased and MMP-9-positive reaction was decreased by 71%. Tissue damage such as epithelial cell hyperplasia, infiltration of granulocyte and lymphocyte, and capillary distribution were also decreased. The Hataedock method with Douchi maintained skin barrier and inhibited skin-damaging factors via regulating Th2 differentiation. In conclusion, Hataedock has a potential for preventative treatment of AD. Further studies are necessary to investigate the immune-regulating mechanism and verify the safety and efficacy of the Hataedock method.
Abstract
Hataedock is a Korean medical treatment that administers herbal extracts orally to newborn infants. This method is used for alleviating harmful heat and excreting fetal wastes by meconium. The purpose of this study was to evaluate anti-inflammatory effect of Hataedock method with Douchi on 2,4-dinitrofluorobenzene (DNFB)-induced atopic dermatitis (AD). The 3-week-old NC/Nga mice were divided into 3 groups: the control group (Ctrl), the AD-induced group (AE), and the Hataedock-treated group (GT). Only the GT group was treated with Hataedock at the 3rd week. After 28 days from Hataedock treatment, we induced AD-like dermatitis to the AE and GT group by DNFB. The effects of Hataedock were evaluated by immunohistochemical method. In the epithelium, PKC-positive reaction of the GT group was decreased by 57%. In the dermal papillae, IL-4-positive reaction was decreased by 34%. In the dermis, the distribution of degranulated mast cells was decreased and substance P-positive reaction was decreased by 49%. In the skin tissue, edema was decreased and MMP-9-positive reaction was decreased by 71%. Tissue damage such as epithelial cell hyperplasia, infiltration of granulocyte and lymphocyte, and capillary distribution were also decreased. The Hataedock method with Douchi maintained skin barrier and inhibited skin-damaging factors via regulating Th2 differentiation. In conclusion, Hataedock has a potential for preventative treatment of AD. Further studies are necessary to investigate the immune-regulating mechanism and verify the safety and efficacy of the Hataedock method.
참고문헌 (34)
- Korean Dermatological Association Textbook Compilation Committee, "Dermatology", pp.170~171 (2008), RyoMoonGak
- Blume-Peytavi, U., "Atopic dermatitis in children: management of pruritus", J. Eur. Acad. Dermatol. Venereol., 26, pp.2~8 (2012)
- Addor, F. A., "Atopic dermatitis: correlation between non-damaged skin barrier function and disease activity", Int. J. Dermatol., 51, pp.672~676 (2012)
- Kabashima, K., "New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity", J. Invest. Dermatol., 70, pp.3~11 (2013)
- Leung, D. Y., "Atopy dermatitis: new insight and opportunities for therapeutic intervention", J. Allergy Clin. Immunol., 105, pp.860~867 (2000)
- Beltrani, V. S., "The role of house dust mites and other aeroallergens in atopic dermatitis", Clin. Dermatol., 21(3), pp.177~182 (2003)
- Jiangyu, "Practical TCM Pediatrics" (2005), Shanghai Science and Technology Press
- Kang, M. Y., "A study on fetal toxicosis removal therapy", J. Pediatr. Korean Med., 17(1), pp.29~51 (2003)
- 임광모, "알레르기성 질환에 대한 한의학적 접근", 동의생리병리학회지, 16(5), pp.1~839 (2002), 한의병리학회
- Miller, A. K., "Anti-inflammatory effects of natural product formulations on murine dendritic cells", J. Diet Suppl., 1, pp.19~33 (2011)
- Yeh, C. Y., "A legume product fermented by Saccharomyces cerevisiae modulates cutaneous atopic dermatitis-like inflammation in mice", BMC Complement. Altern. Med., 14, pp.194~ (2014)
- Sandstrom, M. H., "Prognosis and prognostic factors in adult patient with atopic dermatitis : a long-term follow-up qeustionnaire study", Br. J. Dermatol., 150, pp.103~110 (2004)
- Dupuy, P., "Does atopic dermatitis result from cytokine dysregulation?", J. invest. Dermatol., 92, pp.44~47 (1994)
- Cork, M. J., "Epidermal barrier dysfunction in atopic dermatitis", J. Invest. Dermatol., 129(8), pp.1892~1908 (2009)
- Ye, Y. M., "Overexpression of Epidermal Filaggrin in Patients with Chronic Idiopathic Urticaria Correlates with Urticaria Severity", J. Allergy Clin. Immunol., 131(2), pp.AB56~ (2013)
- Kim, J. W., "Allergy and immunological perspective in atopic dermatitis", J. of Korean Dermatological Association, 41(6), pp.687~689 (2003)
- Ahn, P. S., "Effect of recombinant interferon gamma on the treatment of atopic dermatitis", J. Immunol., 16(3), pp.291~298 (1996)
- 성현철, "아토피피부염에서 임상적 중증도에 따른 알레르기 검사소견", 대한피부과학회지, 44(9), pp.1051~1057 (2006), 대한피부과학회
- Sidbury, R., "Old, New, And Emerging Therapies for Atopic Dermatitis", Dermatologic Clinics., 18(1), pp.1~11 (2000)
- Schreiber, S. L., "The mechanism of action of cyclosporin A and FK506", Immunol. Today, 13(4), pp.136~142 (1992)
- Kim, S. H., "The effects of PG102, a water-soluble extract from actinidia arguta, on serum total IgE levels：a double-blind, randomized, placebo-controlled exploratory clinical study", Eur. J. Nutr., 50(7), pp.523~529 (2011)
- Kim, D., "Anti-allergic effects of PG102, a water-soluble extract prepared from actinidia arguta, in a murine ovalbumin-induced asthma model", Clin. Exp. Allergy, 39(2), pp.280~289 (2009)
- 이현희, "아토피피부염과 피부장벽", Allergy Asthma & Respiratory Diseases, 19(2), pp.95~105 (2009), 대한 소아알레르기 호흡기학회
- Connelly, L., "Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide", J. Immunol., 166(6), pp.3873~3881 (2001)
- Chen, L., "IL-4 Induces Differentiation and Expansion of Th2 Cytokine-Producing Eosinophils", J. Immunol., 172(4), pp.2059~2066 (2004)
- Marsland, B. J., "Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses", J. Exp. Med., 200(2), pp.181~189 (2004)
- Amin, K., "The role of mast cells in allergic inflammation", Respir. Med., 106(1), pp.9~14 (2012)
- Park, S. W., "Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions", J. Neurosurg, 107(3), pp.593~599 (2007)
- Donkin, J. J., "Substance P in traumatic brain injury", Prog. Brain Res., 161, pp.97~109 (2007)
- Ebner, K., "The role of substance P in stress and anxiety responses", Amino Acids, 31(3), pp.251~272 (2006)
- Yamaoka, J., "Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice", J. Dermatol. Sci., 48(2), pp.123~132 (2007)
- Woessner, J.F.Jr., "MMPs and TIMPs-an historical perspective", Mol. Biotechnol., 22(1), pp.33~49 (2002)
- Burrage, P. S., "Matrix metalloproteinases ; role in arthritis", Front Biosci, 11, pp.529~543 (2006)
- Onodera, S., "Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblast of rheumatoid arthritis", J. Biol. Chem., 275(1), pp.444~450 (2000)